Rottendorf Pharma GmbH has continued its global expansion with the addition of offices in Chicago and the establishment of the Rottendorf Pharma, Inc. subsidiary. Gordon Haines has been appointed chief executive officer of Rottendorf Pharma. Inc., which will initially focus its efforts on developing markets through business development and supply chain activities in the U.S. Manufacturing operations in Germany and Europe will initially support these efforts, with plans for a U.S.-based packaging operation. The company will keep its technical areas of formulation, development and bulk manufacturing in Europe for now.

Rottendorf has supplied products for the U.S. market for the last four years from its FDA-approved production facility in Germany. According to the company, the establishment of Rottendorf Pharma, Inc. demonstrates its commitment to expanding the U.S. market presence and providing “home-based” services to U.S./American customers.